KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Gross Profit: 2020-2024

Historic Gross Profit for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to $263.7 million.

  • Esperion Therapeutics' Gross Profit rose 33.99% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 26.65%. This contributed to the annual value of $263.7 million for FY2024, which is 260.92% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Gross Profit of $263.7 million as of FY2024, which was up 260.92% from $73.1 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Gross Profit ranged from a high of $263.7 million in FY2024 and a low of $48.5 million during FY2022.
  • Moreover, its 3-year median value for Gross Profit was $73.1 million (2023), whereas its average is $128.4 million.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 71.47% in 2021, then skyrocketed by 260.92% in 2024.
  • Esperion Therapeutics' Gross Profit (Yearly) stood at $225.2 million in 2020, then crashed by 71.47% to $64.2 million in 2021, then dropped by 24.48% to $48.5 million in 2022, then soared by 50.63% to $73.1 million in 2023, then skyrocketed by 260.92% to $263.7 million in 2024.